{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Phadnis S"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["101609"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10774869"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(6)"],"pubmed_abstract":["<h4>Background</h4>Combined use of inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF-2) receptors is a potential strategy to overcome resistance to either class of drugs when used alone.<h4>Patients and methods</h4>We designed a phase 1 trial to test the drug combination of a multikinase VEGF receptor 2 inhibitor, vandetanib, and an mTOR inhibitor, everolimus, in a pediatric and young adult patient cohort with advanced cancers. Exceptional responders were probed for tumor mutational profile to explore possible molecular mechanisms of response.<h4>Results</h4>Among 21 enrolled patients, clinical benefit was observed in 38% (one patient with partial response and eight patients with stable disease) with a median progression-free survival of 3.3 mo"],"journal":["ESMO open"],"pubmed_title":["Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study."],"pmcid":["PMC10774869"],"funding_grant_id":["U01 CA180964","P30 CA016672","UL1 TR000371","R01 CA273168","R01 CA242845"],"pubmed_authors":["Meric-Bernstam F","Gorlick R","Subbiah V","Subbiah IM","Amini B","Daw NC","Phadnis S","Piha-Paul SA","Zaky W","Gouda MA","Herzog CE","Morani AC","Schwartz CL","Wang X","Harrison DJ"],"additional_accession":[]},"is_claimable":false,"name":"Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.","description":"<h4>Background</h4>Combined use of inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF-2) receptors is a potential strategy to overcome resistance to either class of drugs when used alone.<h4>Patients and methods</h4>We designed a phase 1 trial to test the drug combination of a multikinase VEGF receptor 2 inhibitor, vandetanib, and an mTOR inhibitor, everolimus, in a pediatric and young adult patient cohort with advanced cancers. Exceptional responders were probed for tumor mutational profile to explore possible molecular mechanisms of response.<h4>Results</h4>Among 21 enrolled patients, clinical benefit was observed in 38% (one patient with partial response and eight patients with stable disease) with a median progression-free survival of 3.3 mo","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-01T17:18:50.356Z","creation":"2024-11-14T02:57:32.152Z"},"accession":"S-EPMC10774869","cross_references":{"pubmed":["37879233"],"doi":["10.1016/j.esmoop.2023.101609"]}}